Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4005130 in severe alopecia areata
NCT07533006Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2026
- Primary completion
- Jun 2027
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in alopecia areata comparing LY4005130 with Placebo (2 arms). Primary endpoint: Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Less than or Equal to 20 at 24 weeks. Started Apr 2026; status: recruiting.
02
Drugs
LY4005130
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT07533006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07533006.